Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
Open Access
- 20 March 2020
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (1) , 277-279
Abstract
No abstract availableFunding Information
- Georg-August-Universität Göttingen
This publication has 14 references indexed in Scilit:
- Idelalisib for the treatment of non-Hodgkin lymphomaExpert Opinion on Pharmacotherapy, 2016
- The H1047R point mutation in p110 alpha changes the morphology of human colon HCT116 cancer cellsCell Death Discovery, 2015
- Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomesExpert Review of Hematology, 2015
- Oncogenic Mechanisms in Burkitt LymphomaCold Spring Harbor Perspectives in Medicine, 2014
- Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signalingCancer Management and Research, 2014
- The genetic landscape of mutations in Burkitt lymphomaNature Genetics, 2012
- Burkitt's lymphomaThe Lancet, 2012
- PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphomaBlood, 2012
- Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical featuresLeukemia, 2005
- LY294002-Mediated Inhibition of Phosphatidylinositol 3-Kinase Activity Triggers Growth Inhibition and Apoptosis in CD40-Triggered Ramos–Burkitt Lymphoma B CellsCellular Immunology, 1998